PFKR
Alternative Names: anti-CX3CR1 antibodyLatest Information Update: 21 Sep 2023
At a glance
- Originator Chiome Bioscience
- Developer Chiome Bioscience; National Center of Neurology and Psychiatry
- Class Antibodies
- Mechanism of Action CX3C chemokine receptor 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 28 Aug 2023 Chiome Bioscience has patent pending for PFKR (Chiome Bioscience website, August 2023).
- 28 Aug 2023 Preclinical trials in Multiple sclerosis in Japan (Parenteral) (Chiome Biosciences website, August 2023)